期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

补体受体1型的结构功能及sCR1基因克隆表达的策略 被引量：1

Structure and function of CR1 and proposal of cloning and high-level expression of sCR1
下载PDF
导出
摘要 补体受体1型(Comp lem ent receptor type 1,CR1)具有外源性及内源性活性,既可灭活组装于非自身细胞膜上的C3/C5转化酶,也可灭活自身细胞膜上形成的C3/C5转化酶。CR1是唯一既对经典、替代及植物凝集素(MBL)3个补体激活途径的,对C3/C5转化酶拥有衰变加速活性,又有辅助1因子裂解C3b和C4b作用的补体调节蛋白。对补体分子的过度活化具有抑制和调节作用,在防治补体介导的缺血再灌注损伤以及异种器官移植超急性排斥反应等疾病中具有广阔的应用前景。本文主要综述CR1的结构功能及生物学活性,sCR1基因的克隆与表达及在创伤、缺血再灌注损伤中的应用研究现状。 Complement receptor type 1 shows endogenous and exogenous activity,which can deactivate the C3/C5 convertase on not-self self cytomembrane.CR1 has activation to the three pathways of completent activation to enhance decay of the C3/C5 convertase and helps factor 1 to split C3b and C4b.Because of its inhibition and adjustment to over-activation of complement,it has good future to be used prevention and cure of ischemical reperfusion injury and xeno-organ transplantation.This article mainly overviewed the structure and function of CR1 and proposal of cloning and high-level expression of sCR1 including exploratory development current situation of ischemical reperfusion injury and trauma.
作者 罗雪 汪正清
机构地区 第三军医大学基础部微生物教研室
出处 《创伤外科杂志》 2005年第6期475-477,共3页 Journal of Traumatic Surgery
基金 国家自然科学基金资助项目(30471723) 重庆市卫生局基金项目(00-2015)
关键词 补体 受体 生物学活性 基因 克隆 complement receptor biological activation gene clone
分类号 Q343.1 [生物学—遗传学]
  • 相关文献

参考文献18

  • 1Smith GP,Smith RA.Membrane-targeted complement inhibitors[J].Mol Immunol,2001,38(2-3):249-255.
  • 2Klickstein LB,Wong WW,Smith JA,et al.Human C3b/C4b receptor (CR1).Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3/C4-binding proteins[J].Exp Med,2003,165:1095-1112.
  • 3Sahu A,Kay BK,Lambris JD.Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library[J].Immunol,1996,157:884-891.
  • 4Sahu A,Morikis D,Lambris JD.Compstatin,a peptide inhibitor of complement,exhibits species-specific binding to complement component C3[J].Mol. Immunol,2003,39:557-566.
  • 5Brian OS,Rosie L,Mallin D,et al.Structure of the C3b Binding Site of CR1 (CD35),the Immune Adherence Receptor[J].Cell,2002,108(6):769-780.
  • 6McLure CA,Williamson JF,Stewart BJ,et al.Genomic analysis reveals a duplication of eight rather than seven short comsensus repeats in primate CR1 and CR1L[J].Immunogenetics,2004,56(9):631-638.
  • 7Malgorzata KG,Joann MM,John P.Atkinson.Human complement receptor type 1 (CR1) binds to a major malarial adhesion[J].Trends Mol Medi,2002,8(11):531-537.
  • 8Klickstein LB,Bartow TJ,Miletic V,et al.Identification of distinct C3b and 4Cb recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis [J].Exp Med,1988,168(5):1699-1717.
  • 9Makrides SC,Nygren PA,Andrews B,et al.Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor[J].Pharmacol Exp Ther,1996,277:534-542.
  • 10Paul BM,Claire LH.Complement therapeutics:history and current progress[J].Mol Immunol,2003,40(2-4):159-170.

同被引文献8

  • 1罗雪,汪正清.人sCR1结合C3b结构域基因的克隆及在大肠杆菌中高效表达[J].第三军医大学学报,2005,27(15):1551-1554. 被引量：7
  • 2萨姆布鲁克J 拉塞尔DW 黄培堂 译.分子克隆实验指南[M](第3版)[M].北京:科学出版社,2002.463-465.
  • 3Ishii N,Kato H,Wang P H.Observation by electron microscopy on recombinant soluble human complement receptor type 1 (sCR1) and its derivative,aglyco-sCR1,from CHO cells[J].Enzyme Microb Technol,2003,33(4):482-487.
  • 4Morgan B P,Rushmere N K,Harris C L.Therapeutic uses of recombinant complement receptors[J].Biochem Soc Trans,1998,26(1):49-54.
  • 5Hart M L,Walsh M C,Stahl G L.Initiation of complement activation following oxidative stress.In vitro and in vivo observations[J].Mol Immunol,2004,41(2-3):165-171.
  • 6Weisman H F,Bartow T,Leppo M K,et al.Soluble human complement receptor type 1:in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis[J].Science,1990,249(4965):146-151.
  • 7Quigg R J.Use of complement inhibitors in tissue injury[J].Trends Mol Med,2002,8(9):430-436.
  • 8Lazar H L,Bokesch P M,Van-Lenta F,et al.Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass[J].Circulation,2004,110(11 Suppl 1):Ⅱ274-Ⅱ279.

引证文献1

二级引证文献6

创伤外科杂志
2005年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部